These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 36513631)

  • 1. BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
    Tancredi A; Gusyatiner O; Bady P; Buri MC; Lomazzi R; Chiesi D; Messerer M; Hegi ME
    Cell Death Dis; 2022 Dec; 13(12):1037. PubMed ID: 36513631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
    Wu Q; Berglund AE; Macaulay RJ; Etame AB
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
    Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
    Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.
    Brawanski KR; Sprung S; Freyschlag CF; Hoeftberger R; Ströbel T; Haybaeck J; Thomé C; Manzl C; Birkl-Toeglhofer AM
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.
    Moen EL; Stark AL; Zhang W; Dolan ME; Godley LA
    Mol Cancer Ther; 2014 May; 13(5):1334-44. PubMed ID: 24568970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
    Kitange GJ; Mladek AC; Carlson BL; Schroeder MA; Pokorny JL; Cen L; Decker PA; Wu W; Lomberk GA; Gupta SK; Urrutia RA; Sarkaria JN
    Clin Cancer Res; 2012 Aug; 18(15):4070-9. PubMed ID: 22675172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma.
    Gonzalez-Aponte MF; Damato AR; Trebucq LL; Simon T; Cárdenas-García SP; Cho K; Patti GJ; Golombek DA; Chiesa JJ; Rubin JB; Herzog ED
    J Neurooncol; 2024 Feb; 166(3):419-430. PubMed ID: 38277015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
    Gupta SK; Kizilbash SH; Carlson BL; Mladek AC; Boakye-Agyeman F; Bakken KK; Pokorny JL; Schroeder MA; Decker PA; Cen L; Eckel-Passow JE; Sarkar G; Ballman KV; Reid JM; Jenkins RB; Verhaak RG; Sulman EP; Kitange GJ; Sarkaria JN
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26615020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
    Cabrini G; Fabbri E; Lo Nigro C; Dechecchi MC; Gambari R
    Int J Oncol; 2015 Aug; 47(2):417-28. PubMed ID: 26035292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
    Kohsaka S; Wang L; Yachi K; Mahabir R; Narita T; Itoh T; Tanino M; Kimura T; Nishihara H; Tanaka S
    Mol Cancer Ther; 2012 Jun; 11(6):1289-99. PubMed ID: 22532597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
    Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma.
    Yang E; Hong B; Wang Y; Wang Q; Zhao J; Cui X; Wu Y; Yang S; Su D; Liu X; Kang C
    Cancer Lett; 2024 Apr; 588():216812. PubMed ID: 38490327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
    Okada M; Sato A; Shibuya K; Watanabe E; Seino S; Suzuki S; Seino M; Narita Y; Shibui S; Kayama T; Kitanaka C
    Int J Oncol; 2014 Feb; 44(2):591-9. PubMed ID: 24316756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.
    Liu J; Wang K; Zhu Q; Zhang Y; Chen Y; Lou Z; Yuan J
    CNS Neurosci Ther; 2024 Apr; 30(4):e14711. PubMed ID: 38644551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
    Struve N; Binder ZA; Stead LF; Brend T; Bagley SJ; Faulkner C; Ott L; Müller-Goebel J; Weik AS; Hoffer K; Krug L; Rieckmann T; Bußmann L; Henze M; Morrissette JJD; Kurian KM; Schüller U; Petersen C; Rothkamm K; O Rourke DM; Short SC; Kriegs M
    Oncogene; 2020 Apr; 39(15):3041-3055. PubMed ID: 32066879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells.
    Tsuji S; Nakamura S; Shoda K; Yamada T; Shimazawa M; Nakayama N; Iwama T; Hara H
    J Neurooncol; 2022 Nov; 160(2):375-388. PubMed ID: 36308592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.
    Zhao J; Yang S; Cui X; Wang Q; Yang E; Tong F; Hong B; Xiao M; Xin L; Xu C; Tan Y; Kang C
    Neuro Oncol; 2023 May; 25(5):857-870. PubMed ID: 36272139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Hegi ME; Genbrugge E; Gorlia T; Stupp R; Gilbert MR; Chinot OL; Nabors LB; Jones G; Van Criekinge W; Straub J; Weller M
    Clin Cancer Res; 2019 Mar; 25(6):1809-1816. PubMed ID: 30514777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.